Advanced Medical Isotope (RDGL), formerly known as Advanced Medical Isotope Corporation, develops and commercializes radiation oncology medical devices for the treatment of non-resectable tumors in humans and animals. Its flagship products include a yttrium-90 based injectable particle-gel brachytherapy device for cancerous tumors and an animal-specific IsoPet implant for solid tumors. The company, headquartered in Richland, Washington and incorporated in 1994, has positioned its technology in both human oncology and veterinary markets, targeting niche indications with limited direct competition.

Insiders hold 18.5% of RDGL’s outstanding shares, indicating significant management alignment with shareholders. Institutional ownership data is not publicly reported for RDGL, reflecting its status as an over-the-counter security with limited coverage by large money managers. The high insider stake may support stability in strategic decision-making but also concentrates voting power among executive leadership.

For the most recent fiscal period, RDGL reported gross revenues of approximately $30,000 and a net loss of $2.91 million, translating to a net margin of negative 6,144.90%. Earnings per share data is not available due to the company’s unprofitable status. Return on assets was negative 113.56%, and return on equity is not disclosed. These figures reflect the early-stage commercialization and research costs associated with bringing novel brachytherapy products to market.

RDGL exhibits a beta of negative 0.50, suggesting that its share price movements are inversely correlated with broader market indices and may offer diversification benefits but also carry unpredictability. The absence of analyst coverage and a lack of widely available financial disclosures increase the investment risk. Investors should consider the company’s narrow revenue base, ongoing cash burn, and dependence on product adoption in specialized medical and veterinary markets.